Syra Health SEC Filings

Syra Health Corp. is asking stockholders to vote at its July 23, 2026 annual meeting on three items: electing five directors, ratifying M&K CPAS, PLLC as independent auditor for 2026, and expanding the 2022 Omnibus Equity Incentive Plan to 4,100,000 Class A shares.

As of May 28, 2026, there were 13,839,169 Class A shares and 350,000 Class B shares outstanding, with Class B carrying 16.5 votes per share. The proxy details board independence, committee structures, and director pay, including cash retainers and stock options. It also outlines executive compensation and new CEO Gregory R. Alexander’s employment terms, including a $251,000 base salary and sizable equity awards tied to time-based vesting, performance goals, and potential change-in-control treatment.

Syra Health Corp. reported a profitable quarter for the three months ended March 31, 2026, with net revenues of $2,273,520, up about 22% from 2025, and net income of $240,979 versus a prior-year loss. Growth was driven by a $557,961 increase in population health revenue, partly offset by lower healthcare workforce revenue.

Gross profit rose to $971,255, lifting gross margin to roughly 43% as operating expenses fell by $282,218. Cash and cash equivalents increased to $2,922,318 and working capital to $2,345,509. However, management states there is still substantial doubt about the company’s ability to continue as a going concern, noting an accumulated deficit of $9,479,547 and the need to raise additional capital. The business remains highly dependent on government-related contracts and faces funding pressure from changes in U.S. federal spending.

Syra Health Corp. reported its first profitable quarter in Q1 2026. Net income was $240,979, compared with a net loss of $(472,265) a year earlier. Revenue grew 22% to $2.27 million, driven by population health solutions, which rose 46% to $1.8 million.

Gross margin expanded to 42.7% from 31.7% as the company shifted toward higher-margin offerings and improved operating leverage. Operating expenses declined across salaries, professional services, SG&A, and R&D, supporting adjusted EBITDA of $244,495 versus a loss in 2025. Cash and cash equivalents increased to $2.9 million with strong operating cash flow.

Syra Health Corp. filed Amendment No. 1 to its annual report to add detailed Part III information on directors, executive compensation, ownership and auditor fees, without changing previously issued financial statements. The filing confirms Gregory R. Alexander as Chief Executive Officer effective January 5, 2026 with a base salary of $251,000, equity awards and change‑of‑control protections. It outlines compensation for former leaders, including the prior CEO and president, and notes no bonuses were paid for 2025. The amendment describes board and committee cash retainers, substantial option grants to non‑employee directors, and the 2022 Omnibus Equity Incentive Plan with 1,041,667 shares reserved. It also discloses related‑party service and lease arrangements, major shareholders’ voting power, and audit and audit‑related fees paid to M&K for 2025 and 2024.

Syra Health Corp. filed its annual report describing a small but loss-making healthcare solutions business focused on mental health, population health, digital health, education, and staffing. The company generated approximately $7.2 million of revenue in 2025, down from $8.0 million in 2024, and reported net losses of $896,333 and $3,759,238 for those years. Cash was $1,614,733 as of December 31, 2025, and its auditors expressed substantial doubt about its ability to continue as a going concern, highlighting the need for substantial additional funding. Syra operates in heavily regulated healthcare and government-contract markets and outlines numerous operational, regulatory, technology, data security, concentration, and staffing risks that could materially affect its business. Non-affiliate equity market value was about $979,537 as of June 30, 2025, with 11,339,169 Class A shares outstanding as of March 12, 2026.

Syra Health Corp. reported FY2025 results showing a much smaller loss and stronger margins despite lower revenue. Net revenues were $7.2 million versus $8.0 million in FY2024, mainly due to reduced federal funding to state and county customers.

Population Health revenue grew 157% to $5.3 million, becoming a key growth engine. Net loss narrowed to ($896,333) from ($3,759,238), and earnings per share improved to ($0.08) from ($0.50). Gross margin increased to 34.4% from 20.7% as cost of services fell.

Total operating expenses declined to $3.4 million from $5.4 million, and adjusted EBITDA improved to ($863K) from ($3.7 million). Cash was $1.6 million with no long-term debt as of December 31, 2025, while management highlighted a strategic shift toward integrated healthcare solutions and reiterated a goal of reaching profitability by year-end 2026.

Syra Health Corp. reported that CEO Gregory R. Alexander received new equity awards. On January 5, 2026, he was granted 110,537 restricted stock units at $0.00 per unit and 257,920 stock options with a $0.09 exercise price.

For both grants, 20% vest one year after the grant date. The remaining 80% vest in equal installments over the following four years on each anniversary of the grant date, aligning his compensation with longer-term company performance.

Syra Health Corp shareholder Neil Johnson filed a Schedule 13D reporting beneficial ownership of 700,312 shares of Class A common stock, representing 6.2% of the company. Johnson, an individual based in Ohio who works in consulting, acquired the position using personal funds. The filing notes that his purpose of transaction is "Influence," indicating he may seek to play an active role in matters affecting the company.

The disclosure also shows that on January 13, 2026, Johnson was involved in a transaction for 38,182 shares at a price of $0.085 per share. He reports sole voting power over 700,312 shares, with no shared voting or dispositive power, and no disclosed contracts or arrangements related to these securities.

Syra Health Corp's chief executive officer reports no beneficial ownership of company securities. A Form 3 initial statement of beneficial ownership was filed for Gregory R. Alexander, who is identified as the Chief Executive Officer of Syra Health Corp (ticker SYRA). The filing shows no non-derivative or derivative securities listed in the ownership tables, and the explanation section states that no securities are beneficially owned. This means the CEO is not reporting ownership of Syra Health stock or related derivative instruments as of the event date in this filing.